Search research articles
Contact Us
Filters
Showing results (251-260 of 272) with videos related to
Page
of 28
Sort By:
Trials
|
September 5, 2022
Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial
Dafna D Gladman, Philip J Mease, Paul Bird, et al.
Acta Dermato-Venereologica
|
February 11, 2022
Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data
Alice B Gottlieb, Atul Deodhar, Iain B Mcinnes, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
January 22, 2024
Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic Arthritis
Stefan Siebert, Laura C Coates, Georg Schett, et al.
The Journal of Rheumatology
|
July 1, 2026
Bimekizumab Improves Health Status and Work Productivity, With Reduced Productivity Costs, to 3 Years in Axial Spondyloarthritis and Psoriatic Arthritis
Elena Nikiphorou, William Tillett, Atul Deodhar, et al.
Nature Reviews. Rheumatology
|
November 27, 2025
Consensus definitions of complex-to-manage and treatment-refractory psoriatic arthritis: a GRAPPA initiative
Fabian Proft, Andre L Ribeiro, Shikha Singla, et al.
The Lancet. Rheumatology
|
January 30, 2024
Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies
Philip J Mease, Philip S Helliwell, Dafna D Gladman, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
April 1, 2024
Effect of Secukinumab Versus Adalimumab Biosimilar on Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: Results From a Head-to-Head Randomized Phase IIIb Study
Xenofon Baraliakos, Mikkel Østergaard, Denis Poddubnyy, et al.
Annals of the Rheumatic Diseases
|
November 6, 2019
Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)
Maxime Dougados, James Cheng-Chung Wei, Robert Landewé, et al.
Annals of Internal Medicine
|
September 27, 2021
The Safety and Immunologic Effectiveness of the Live Varicella-Zoster Vaccine in Patients Receiving Tumor Necrosis Factor Inhibitor Therapy : A Randomized Controlled Trial
Jeffrey R Curtis, Stacey S Cofield, S Louis Bridges, et al.
RMD Open
|
February 11, 2021
Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced
Christopher T Ritchlin, Philip S Helliwell, Wolf-Henning Boehncke, et al.
Page
of 28
Search research articles
Search
Showing results (251-260 of 272) with videos related to
Sort By:
Page
of 28
Trials
|
September 5, 2022
Efficacy and safety of guselkumab in biologic-naïve patients with active axial psoriatic arthritis: study protocol for STAR, a phase 4, randomized, double-blinded, placebo-controlled trial
Dafna D Gladman, Philip J Mease, Paul Bird, et al.
Acta Dermato-Venereologica
|
February 11, 2022
Long-term Safety of Secukinumab Over Five Years in Patients with Moderate-to-severe Plaque Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis: Update on Integrated Pooled Clinical Trial and Post-marketing Surveillance Data
Alice B Gottlieb, Atul Deodhar, Iain B Mcinnes, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
January 22, 2024
Modulation of Interleukin-23 Signaling With Guselkumab in Biologic-Naive Patients Versus Tumor Necrosis Factor Inhibitor-Inadequate Responders With Active Psoriatic Arthritis
Stefan Siebert, Laura C Coates, Georg Schett, et al.
The Journal of Rheumatology
|
July 1, 2026
Bimekizumab Improves Health Status and Work Productivity, With Reduced Productivity Costs, to 3 Years in Axial Spondyloarthritis and Psoriatic Arthritis
Elena Nikiphorou, William Tillett, Atul Deodhar, et al.
Nature Reviews. Rheumatology
|
November 27, 2025
Consensus definitions of complex-to-manage and treatment-refractory psoriatic arthritis: a GRAPPA initiative
Fabian Proft, Andre L Ribeiro, Shikha Singla, et al.
The Lancet. Rheumatology
|
January 30, 2024
Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies
Philip J Mease, Philip S Helliwell, Dafna D Gladman, et al.
Arthritis & Rheumatology (Hoboken, N.J.)
|
April 1, 2024
Effect of Secukinumab Versus Adalimumab Biosimilar on Radiographic Progression in Patients With Radiographic Axial Spondyloarthritis: Results From a Head-to-Head Randomized Phase IIIb Study
Xenofon Baraliakos, Mikkel Østergaard, Denis Poddubnyy, et al.
Annals of the Rheumatic Diseases
|
November 6, 2019
Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)
Maxime Dougados, James Cheng-Chung Wei, Robert Landewé, et al.
Annals of Internal Medicine
|
September 27, 2021
The Safety and Immunologic Effectiveness of the Live Varicella-Zoster Vaccine in Patients Receiving Tumor Necrosis Factor Inhibitor Therapy : A Randomized Controlled Trial
Jeffrey R Curtis, Stacey S Cofield, S Louis Bridges, et al.
RMD Open
|
February 11, 2021
Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced
Christopher T Ritchlin, Philip S Helliwell, Wolf-Henning Boehncke, et al.
Page
of 28